Highlights Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
25.95 ^USD	+1.01%		-0.19%	+95.11%

May. 02	Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Dyne Therapeutics Reportedly Mulling Options After Takeover Interest Received	Jan. 26	MT
Dyne Therapeutics Reportedly Seeing Takeover Interest, Weighing Options	Jan. 25	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Traders Await Rate Cut Hints in Policy Meeting Readout	Jan. 03	MT
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE? Platform in Developing Therapeutics for Rare Muscle Diseases	Jan. 03	CI
Dyne Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Dyne Therapeutics Gets FDA's Orphan Drug Designation For DYNE-101	23-09-20	MT
Dyne Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Dyne Therapeutics Says European Medicines Agency Granted Orphan Drug Designation for DYNE-101	23-05-25	MT
Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Dyne Therapeutics Present New Preclinical Data At ASGCT Annual Meeting Demonstrating Force(TM) Platform Delivery to CNS	23-05-02	CI
Dyne Therapeutics Gets FDA Orphan Drug, Rare Pediatric Labels for Duchenne Muscular Dystrophy Treatment	23-03-23	MT
Dyne Therapeutics, Inc. Receives FDA Orphan Drug and Rare Pediatric Designations for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy	23-03-23	CI
Dyne Therapeutics Q4 Loss Narrows	23-03-02	MT
DYNE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-02	AQ
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
Dyne Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
DYNE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Highlights

Filters